It’s a historic day for New Zealanders with the most aggressive form of breast cancer, as Pharmac announces a consultation that would see pembrolizumab (brand name Keytruda) funded for people with advanced triple negative breast cancer (TNBC) from 1 October.
Keytruda will be the first…
[ad_2]
Source link
